Genetics

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 9, 2022 - 2:00am
Legal, Professional Services, P.C, Telephone, Anti-Kickback Statute, SEC, DOJ, Securities Exchange Act of 1934, Remuneration, Genetics, Battle of Saint-Fulgent, Company, Exchange, NASDAQ, Jeanne Eagels, News, Stark, Private investigator

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT) on behalf of Fulgent stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT) on behalf of Fulgent stockholders.
  • Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Fulgent released its financial results for the second quarter of 2022 on August 4, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

Retrieved on: 
Monday, August 8, 2022 - 11:36pm
MDS, Leadership, Sickle cell disease, Genetics, Employment, Achievement, Nasdaq, Thalassemia, Agios Pharmaceuticals, GLOBE, PK, Pyruvate kinase deficiency, Anemia, Pharmaceutical industry

The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement grants consisted of (i) a nonstatutory option to purchase up to 561,083 shares of common stock, (ii) restricted stock units for 68,073 shares of common stock and (iii) performance stock units for 170,183 shares of common stock.
  • The option has an exercise price of $29.38 per share, the closing price per share of the companys common stock as reported by Nasdaq on August 8, 2022.
  • Each restricted stock unit will entitle Mr. Goff to receive one share of the companys common stock for each restricted stock unit that vests.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:01pm
FDA, Tremor, Part, CNS, GLOBE, Investment, Therapeutic index, ET, Modified active gas sampling, Patient, ADL, Central nervous system, Safety, Epilepsy, NASDAQ, Â, Genetics, Essential tremor, Pharmaceutical industry, Praxis

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022.

Key Points: 
  • The Company expects topline results from the ongoing PRAX-944 Essential1 Study in the fourth quarter of 2022.
  • In June 2022, following the PRAX-114 Aria Study results, the Company discontinued the PRAX-114 Phase 2 study for the treatment of ET.
  • Second Quarter 2022 Financial Results:
    As of June 30, 2022, Praxis had $165.4 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash, cash equivalents and marketable securities as of December 31, 2021.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors

Retrieved on: 
Monday, August 8, 2022 - 5:00pm
Class Action Lawsuit, Professional Services, Legal, FDA, Press, Real estate investment trust, Industry, Associated Press, Anti-Kickback Statute, SEC, DOJ, Investment, Securities Exchange Act of 1934, GPM, SCAS, Remuneration, Information technology, Battle of Saint-Fulgent, Genetics, U.S. Department of Justice Office of Legislative Affairs, U.S. Department of Commerce Office of Security, Company, Person, Program, NASDAQ, Exchange, Bloomberg Businessweek, Publication, News, Financial Times, Insurance, Stark, The Wall Street Journal, Justice, Pharmaceutical industry, Reuters, Forbes

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Fulgents stock fell as much as 8% during intraday trading on August 5, 2022, thereby injuring investors.
  • Whistleblower Notice: Persons with non-public information regarding Fulgent should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Monday, August 8, 2022 - 2:22pm
Class Action Lawsuit, Professional Services, Legal, Suite, Anti-Kickback Statute, SEC, DOJ, Securities Exchange Act of 1934, Remuneration, Genetics, Battle of Saint-Fulgent, Company, Exchange, NASDAQ, News, Ethics, Stark, Certification, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Fulgent released its financial results for the second quarter of 2022 on August 4, 2022.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Retrieved on: 
Monday, August 8, 2022 - 1:00pm
Oncology, Health, Genetics, Other Health, Research, Science, FDA, U.S. Securities and Exchange Commission, Cell, Hematology, Private Securities Litigation Reform Act, SEC, Facebook, NK, Security (finance), Lymphatic system, Patient, Review, Instagram, COVID-19, Twitter, Therapy, Risk, Immunotherapy, BLA, Webcast, NAM, LinkedIn, Pharmaceutical industry

ET to review its second quarter 2022 financial results and provide an update on the company.

Key Points: 
  • ET to review its second quarter 2022 financial results and provide an update on the company.
  • A live webcast of the conference call can be accessed in the Investors & Media section of Gamida Cells website at www.gamida-cell.com .
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

Cyclo Therapeutics to Present at the China NPC Association Meeting

Retrieved on: 
Monday, August 8, 2022 - 1:05pm
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, U.S. Securities and Exchange Commission, Association, Risk, Expanded access, Diagnosis, Niemann–Pick disease, Disease, Security (finance), Caregiver, Research, Patient, Therapy, Company, NPC, Awareness, Doctor of Philosophy, Form 10-K, Protocol, Science, Nasdaq, MD, CYTH, Pharmaceutical industry, Cyclo

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen, China.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen, China.
  • We are pleased to participate in a meeting such as this which represents a significant opportunity to connect with patients, caregivers, and all those dedicated to advancing research, understanding, awareness for NPC in China.
  • We are wholeheartedly committed to advancing the clinical development Trappsol Cyclo for the treatment of NPC and look forward to engaging with our global NPC community, commented Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics.
  • This physician, researcher and patient focused event will discuss Niemann-Pick Disease Type C (NPC) and the latest research results for diagnosis and treatment.

Rallybio Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 1:00pm
General Health, Professional Services, Health, Finance, U.S. Securities and Exchange Commission, Blood, R, SEC, IPR, Medicine, Board, Research, Translation, ENPP1, Patient, Anemia, Research and development, G&A, Iron overload, Board of directors, Erythropoiesis, Risk, Precision medicine, CFO, Pregnancy, General Administration of Sport of China, Biotechnology, Corporation, Safety, Nasdaq, Columbia University Irving Medical Center, Pharmacokinetics, Forward-looking statement, Absorption, Degenerative disease, Acquisition, Program, Lists of diseases, Genetics, POC, Woman, Hypophosphatasia, Pediatrics, Hematology, HPP, Population, Microdeletion syndrome, IND, PD, Company, C5, CPA, Columbia University, Manuscript, University, Human, Administration, Pharmaceutical industry, Medical imaging, Risk management, Vaccine, Fine chemical, Sanofi

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments.
  • Rallybio expects to discuss the preliminary platelet elimination data by the end of the third quarter of 2022 and to release PoC data in the first quarter of 2023.
  • Rallybio announced in June 2022 that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO).
  • Second Quarter 2022 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $10.1 million for the second quarter of 2022, compared to $6.8 million for the same period in 2021.